

Financial news for NEO dated on 2020-04-29: Neogenomics Filing Shows Registration For \$100M Common Stock Shelf Offering

Financial news for NEO dated on 2020-04-29: SVB Leerink Maintains Outperform on NeoGenomics, Raises Price Target to \$35

Financial news for NEO dated on 2020-04-28: NeoGenomics Q1 EPS \$(0.020) Misses \$0.020 Estimate, Sales \$106.030M Beat \$104.580M Estimate

Financial news for NEO dated on 2020-04-21: Stephens & Co. Reinstates Overweight on NeoGenomics, Announces \$33 Price Target

Financial news for NEO dated on 2020-04-03: NeoGenomics Highlights Integration Of Indica Labs' HALO AP Image Analysis Platform

Financial news for NEO dated on 2020-03-17: Needham Maintains Buy on NeoGenomics, Raises Price Target to \$33

Financial news for NEO dated on 2020-03-02: Craig-Hallum Reinstates Buy on NeoGenomics, Announces \$38 Price Target

Financial news for NEO dated on 2020-03-02: Raymond James Maintains Outperform on NeoGenomics, Raises Price Target to \$32

Financial news for NEO dated on 2020-02-28: Needham Maintains Buy on NeoGenomics, Raises Price Target to \$32

Financial news for NEO dated on 2020-02-28: Benchmark Maintains Buy on NeoGenomics, Raises Price Target to \$30

Financial news for NEO dated on 2020-02-28: First Analysis Upgrades NeoGenomics to Strong Buy

Financial news for NEO dated on 2020-01-23: First Analysis Downgrades NeoGenomics to Outperform, Announces \$35 Price Target

Financial news for NEO dated on 2019-11-13: NeoGenomics Files Non-timely 10-Q

Financial news for NEO dated on 2019-10-29: NeoGenomics Q3 Adj. EPS \$0.07 Beats \$0.06 Estimate, Sales \$104.672M Beat \$99.1M Estimate

Financial news for NEO dated on 2019-07-31: Raymond James Maintains Outperform on NeoGenomics, Raises Price Target to \$27

Financial news for NEO dated on 2019-07-30: NeoGenomics Q2 EPS \$0.02 Misses \$0.06 Estimate, Sales \$101.713M Beat \$97.3M Estimate

Financial news for NEO dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for NEO dated on 2019-06-27: NeoGenomics Reports New \$250M Credit Deal

Financial news for NEO dated on 2019-05-22: NeoGenomics shares are trading lower after the company announced a common stock public offering of 7 million shares priced at \$21.25 per share.

Financial news for NEO dated on 2019-05-22: NeoGenomics Shares Down 4% Premarket As Co. Late Tues. Priced 7M Shares At \$21.25/Share

Financial news for NEO dated on 2019-05-20: NeoGenomics Reports Commencement Of \$150M Common Stock Offering

Financial news for NEO dated on 2019-04-30: NeoGenomics Q1 EPS \$0.07 Beats \$0.04 Estimate, Sales \$95.577M Beat \$90.61M Estimate

Financial news for NEO dated on 2019-03-11: NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ

Financial news for NEO dated on 2019-02-19: NeoGenomics Sees FY19 Sales \$379M-\$395M vs \$385.69M Est.

Financial news for NEO dated on 2019-02-19: NeoGenomics Q4 EPS \$0.06 Beats \$0.05 Estimate, Sales \$76.475M Beat \$71.43M Estimate

Financial news for NEO dated on 2019-01-09: NeoGenomics shares are trading higher after the company was added to the S&P SmallCap 600.

Financial news for NEO dated on 2019-01-08: S&P Dow Jones Indices Announces 'NeoGenomics Set to Join S&P SmallCap 600,' Will Replace Engility

Financial news for NEO dated on 2019-01-03: Needham Initiates Coverage On NeoGenomics with Buy Rating, Announces \$14 Price Target

Financial news for NEO dated on 2018-12-12: NeoGenomics Announces Pricing On Secondary Offering Of Common Stock By Selling Stockholder

Financial news for NEO dated on 2018-12-11: NeoGenomics Reports ~10.84M Share Common Stock Offering By Selling Shareholder

Financial news for NEO dated on 2018-11-30: QIAGEN And NeoGenomics Announce Master Service Agreement

Financial news for NEO dated on 2018-11-01: Stocks Which Set New 52-Week High Yesterday, October 31st

Financial news for NEO dated on 2018-10-30: Stocks Which Set New 52-Week High Yesterday, October 29th

Financial news for NEO dated on 2018-10-30: NeoGenomics Raises FY18 Adj. EPS Guidance From \$0.12-\$0.17 vs \$0.17-\$0.19 vs \$0.15 Est., Narrows FY18 Sales Guidance From \$260M-\$272M to \$270M-272M vs 268.13M

Financial news for NEO dated on 2018-10-30: NeoGenomics Q3 EPS \$0.02, Inline, Sales \$69.1M Beat \$66.33M Estimate

Financial news for NEO dated on 2018-10-29: Stocks That Made New 52-Week Highs Friday, October 26th

Financial news for NEO dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for NEO dated on 2018-10-01: Neonode Shares Halted For Volatility; Stock Has Been Halted Multiple Times Today, Turn On Benzinga Signals To Be Alerted To All Halts And Resumptions

Financial news for NEO dated on 2018-10-01: Neonode Shares Resume Trade, Up 32.2%

Financial news for NEO dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for NEO dated on 2018-09-12: NeoGenomics Reports Winning Of Clinical Reference Laboratory Testing Services Deal With Premier, No Terms Disclosed

Financial news for NEO dated on 2018-08-21: Leerink Swann Initiates Coverage On NeoGenomics with Outperform Rating, Announces \$18 Price Target

Financial news for NEO dated on 2018-08-10: NeoGenomics Late Thursday Announced 9.8M Share Common Stock Offering Will Be Priced At \$12.75/Share

Financial news for NEO dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for NEO dated on 2018-08-06: NeoGenomics shares trading down 7.2% after the company announced a \$125M common stock offering.

Financial news for NEO dated on 2018-08-06: NeoGenomics Announces \$125M Common Stock Offering

Financial news for NEO dated on 2018-07-24: NeoGenomics Shares Down 18% After Co. Lowered FY18 EPS Outlook from \$0.16-\$0.20 To \$0.12-\$0.17

Financial news for NEO dated on 2018-07-24: NeoGenomics Sees FY18 Sales \$260M-\$272M vs \$265.29M Est.

Financial news for NEO dated on 2018-07-24: NeoGenomics Q2 EPS \$0.07 Beats \$0.04 Estimate, Sales \$67.746M Beat \$66.18M Estimate

Financial news for NEO dated on 2018-06-01: Pharmaceutical Product Development, NeoGenomics Labs Report Formation Of Strategic Alliance To Provide Global Pathology, Molecular Testing Solution To PPD's Pharma, Biotech Clients

Financial news for NEO dated on 2018-05-02: First Analysis Downgrades NeoGenomics to Equal-Weight

Financial news for NEO dated on 2018-05-01: NeoGenomics Reaffirms FY18 Outlook Adj.

EPS \$0.15-\$0.20 vs \$0.17 Est., Sales \$260M-\$272M vs \$263.9M Est.

Financial news for NEO dated on 2018-05-01: Neogenomics Reports Q1 Adj. EPS \$0.04 Beats \$0.03 Est., Sales \$63.42B Beats \$61.21B Est.

Financial news for NEO dated on 2018-04-16: BTIG Research Upgrades NeoGenomics to Outperform

Financial news for NEO dated on 2018-03-20: NeoGenomics Names George Cardoza President Of Pharma Services Division And Sharon Virag As CFO

Financial news for NEO dated on 2018-02-21: NeoGenomics Sees FY18 Adj. EPS \$0.15-\$0.20 vs \$0.21 Est., Sales \$260-\$272M vs \$281M Est.

Financial news for NEO dated on 2018-02-21: NeoGenomics Reports Q4 EPS \$0.05 vs \$0.04 Est., Sales \$67.8M vs \$66.2M Est.

Financial news for NEO dated on 2017-10-25: NeoGenomics Sees Q4 Adj. EPS \$0.04 to \$0.05 vs \$0.04 Est., Sales \$65M to \$67M vs \$67M Est.

Financial news for NEO dated on 2017-10-25: NeoGenomics Q3 Adj. EPS \$0.01 vs \$0.02 Est., Sales \$63.1M vs \$63.9M Est.

Financial news for NEO dated on 2017-10-12: NeoGenomics Sees Q4 Sales \$65M-\$67M vs \$69.1M Est., Adj. EBITDA \$9M-\$10M

Financial news for NEO dated on 2017-10-12: NeoGenomics Reports Prelim. Q3 Results: Sales ~\$63.1M vs \$65.9M Est., Adj. EBITDA ~\$6M

Financial news for NEO dated on 2017-09-11: NeoGenomics Offers Update On Impact From Hurricane Irma: 'had minimal impacts to its Fort Myers, FL facility'

Financial news for NEO dated on 2017-09-11: BTIG Research Downgrades NeoGenomics to Neutral

Financial news for NEO dated on 2017-08-24: Gabelli & Co. Initiates Coverage On NeoGenomics with Buy Rating

Financial news for NEO dated on 2017-07-25: NeoGenomics Reiterates FY 2017 Guidance

Financial news for NEO dated on 2017-07-25: NeoGenomics Q2 EPS \$0.04 vs \$0.03 Est., Sales \$66.1M vs \$63.0M Est

Financial news for NEO dated on 2017-05-15: NeoGenomics Announces Results Of New Clinical Trial Demonstrating Sensitivity Of NeoLAB Liquid Biopsy Prostatetest Was 97% In PRedicting Presence Of High Grade Prostate Cancer While Conventional Biopsies in This Study Was 78%

Financial news for NEO dated on 2017-03-13: NeoGenomics and Definiens Enter Agreement to Develop Novel Assays for Clinical Trials

Financial news for NEO dated on 2017-02-22: NeoGenomics Sees FY17 Adj. EPS \$0.17-\$0.22 vs \$0.21 Est., Sales \$260M-\$275M vs \$274M Est.

Financial news for NEO dated on 2017-02-22: NeoGenomics Reports Q4 Adj. EPS \$0.05 vs \$0.03 Est., Sales \$60.5M vs \$61.8M Est.

Financial news for NEO dated on 2016-12-27: Amended 13D Filing from GE on NeoGenomics Shows 25.4% Stake

Financial news for NEO dated on 2016-12-15: Cantor Fitzgerald Initiates Coverage On NeoGenomics at Overweight, Announces \$11.00 Target

Financial news for NEO dated on 2016-10-04: First Analysis Initiates Coverage on NeoGenomics at Overweight, Announces \$11.00 PT

Financial news for NEO dated on 2016-09-09: Raymond James Initiates Coverage on NeoGenomics at Outperform

Financial news for NEO dated on 2016-07-27: BTIG Research Downgrades NeoGenomics to Neutral

Financial news for NEO dated on 2016-05-11: Roth Capital Assumes NeoGenomics at Buy, Announces \$10.00 PT

Financial news for NEO dated on 2016-03-11: Benchmark Initiates Coverage on NeoGenomics at Buy, Announces \$8.00 PT

Financial news for NEO dated on 2015-10-28: NeoGenomics Announces Amended Strategic

## Alliance Agreement with Covance Central Laboratory Services

Financial news for NEO dated on 2015-06-23: BTIG Research Initiates Coverage on NeoGenomics at Buy, Announces \$7.00 PT

Financial news for NEO dated on 2015-06-22: BTIG Research Initiates Coverage on NeoGenomics at Buy, Announces \$7.00 PT

Financial news for NEO dated on 2014-10-23: NeoGenomics Launches Molecular Test for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia

Financial news for NEO dated on 2014-07-17: Neogenomics Sees Q3 EPS \$(0.01)-0.01 vs \$0.01 Est; Sees Sales \$22.0M-23.50M vs \$20.02M Est

Financial news for NEO dated on 2014-07-17: Neogenomics Reports Q2 EPS of \$0.01, Inline

Financial news for NEO dated on 2014-06-23: Neogenomics Raises Q2 Sales Guidance from \$18.80M-19.30M to \$20.0M-20.50M vs \$18.90M Est, Affirms EPS Outlook

Financial news for NEO dated on 2014-05-12: Roth Capital Initiates Coverage on Neogenomics at Buy, Announces \$6.00 PT

Financial news for NEO dated on 2014-05-12: Longbow Research Initiates Coverage on Neogenomics at Buy, Announces \$6.00 PT

Financial news for NEO dated on 2014-04-23: Neogenomics Sees FY2014 EPS \$0.03-0.05 vs \$0.01 Est; Sees Sales \$73.0M-77.0M vs \$71.91M Est

Financial news for NEO dated on 2014-04-23: Neogenomics Sees Q2 EPS \$0.00-0.01 vs \$(0.01) Est; Sees Sales \$18.80M-19.30M vs \$17.68M Est

Financial news for NEO dated on 2014-04-23: Neogenomics Reports Q1 EPS of \$0.00, Inline; Revenue of \$18.20M vs \$17.68M Est

Financial news for NEO dated on 2014-03-18: NeoGenomics Launches Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

Financial news for NEO dated on 2014-02-19: Neogenomics Sees FY2014 EPS \$0.05-0.07 vs \$0.07 Est; Sees Sales \$73.0M-77.0M vs \$72.81M Est

Financial news for NEO dated on 2014-02-19: Neogenomics Sees Q1 EPS \$0.01-0.02 vs \$0.01 Est

Financial news for NEO dated on 2014-02-19: Neogenomics Reports Q4 EPS of \$0.02, Inline; Revenue of \$18.32M vs \$17.80M Est

Financial news for NEO dated on 2014-02-14: Stephens & Co. Initiates Coverage on Neogenomics at Overweight, Announces \$6.00 PT

Financial news for NEO dated on 2014-01-08: William Blair Initiates Coverage on Neogenomics at Outperform

Financial news for NEO dated on 2014-01-07: NeoGenomics Launches New Test for Detection of Mutations in Calreticulin Gene

Financial news for NEO dated on 2013-11-18: Covance NeoGenomics Enter Strategic Alliance for Anatomic Pathology and Specialty Laboratory Testing Services

Financial news for NEO dated on 2013-07-31: Neogenomics Lowers FY2013 EPS Guidance from \$0.03-0.05 to \$0.01-0.04 vs \$0.04 Est; Lowers FY2013 Sales Guidance from \$68.0M-73.0M to \$63.0M-66.0M vs \$69.50M Est

Financial news for NEO dated on 2013-07-31: Neogenomics Sees Q3 EPS \$0.00-0.01 vs \$0.01 Est; Sees Sales \$15.80M-16.40M

Financial news for NEO dated on 2013-07-31: Neogenomics Reports Q2 EPS of \$0.01 vs \$0.00 Est; Revenue of \$15.60M vs \$16.20M Est

Financial news for NEO dated on 2013-04-25: Ladenburg Thalmann Downgrades Neogenomics to Neutral, Removes \$3.75 PT

Financial news for NEO dated on 2013-02-14: Neogenomics Sees FY2013 EPS \$0.03-0.05 vs \$0.06 Est; Sees Sales \$68.0M-73.0M vs \$70.51M Est

Financial news for NEO dated on 2013-02-14: Neogenomics Sees Q1 EPS \$0.00-0.01 vs \$0.01 Est

Financial news for NEO dated on 2013-02-14: Neogenomics Reports Q4 EPS of \$0.00 vs

\$(0.01) Est; Revenue of \$14.90M vs \$14.88M Est

Financial news for NEO dated on 2013-01-17: Neogenomics Files \$25M Mixed Securities Shelf

Financial news for NEO dated on 2012-12-17: NeoGenomics Launches NeoSITE Barrett's Esophagus FISH Test for Diagnosis of High Grade Dysplasia/Esophageal Cancer